214 related articles for article (PubMed ID: 16155018)
1. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
3. The malignant clone and the bone-marrow environment.
Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
[TBL] [Abstract][Full Text] [Related]
4. Novel biological therapies for the treatment of multiple myeloma.
Richardson PG; Mitsiades CS; Hideshima T; Anderson KC
Best Pract Res Clin Haematol; 2005; 18(4):619-34. PubMed ID: 16026741
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
6. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
7. Oncogenomics to target myeloma in the bone marrow microenvironment.
Anderson KC
Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Mitsiades CS; Mitsiades NS; Richardson PG; Munshi NC; Anderson KC
J Cell Biochem; 2007 Jul; 101(4):950-68. PubMed ID: 17546631
[TBL] [Abstract][Full Text] [Related]
11. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
12. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
18. [Management of multiple myeloma].
Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
Mehta J; Singhal S
Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
[TBL] [Abstract][Full Text] [Related]
20. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]